

Company	Description	Source	Potential Exit Timing	Terms
DiscGenics	Allogeneic (off-the-shelf) cell therapy that regenerates disc volume, dramatically improving pain and mobility for those suffering from lower back pain	Colin Novick of Innovacell is a Board Director	Early 2024	8% CB, 20% discount to next round with \$625M value cap and a "reasonable-ness" upside cap
Schedule1 Therapeutics	Working with the FDA to replace the abused "medical marijuana" market with regulated Cannabinoid medicines for pain, starting with Migraine	Steve Chelberg's Chicago network	Early 2026	8% CB, 20% discount to next round with \$20M valuation cap